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Abstract: Background Agitation is a common, distressing and challenging symptom affecting
large numbers of people with dementia and impacting significantly on quality of life
(QoL). There is an urgent need for evidence-based, cost-effective psychosocial
intervention to improve these outcomes, particularly in the absence of safe, effective
pharmacological therapies. This study aimed to conduct a large and rigorous RCT to
evaluate the efficacy of a person-centered care and psychosocial intervention
(WHELD) on QoL, agitation and antipsychotic use in people with dementia living in
nursing homes, and to determine the cost of the intervention.
Methods and Findings: This was a randomized controlled cluster trial comparing the
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
WHELD intervention with treatment as usual in people with dementia living in 69 UK
nursing homes, using an intention to treat analysis. All nursing homes allocated to the
WHELD intervention received staff training in person-centered care (PCC), social
interaction (SoI) and education regarding antipsychotic medications (AM) followed by
ongoing delivery through a care staff champion model. The primary outcome measure
was QoL (DEMQOL-proxy).  Key secondary outcomes were agitation (Cohen
Mansfield Agitation Inventory), neuropsychiatric symptoms (NPI) and antipsychotic
use. Other secondary outcome measures were global deterioration (CDR), mood
(Cornell Scale for Depression in Dementia CSSD), unmet needs (Camberwell
Assessment of Need in the Elderly -CANE), mortality, quality of interactions (Quality of
Interactions Scale -QUIS), pain (Abbey pain scale) and cost. Intervention costs were
calculated using published cost function figures and compared with usual costs. 847
people were randomized to WHELD or treatment as usual, of whom 553 completed the
nine month RCT. The WHELD intervention conferred a statistically significant
improvement in QoL compared to treatment as usual over nine months (DEMQOL
proxy z score 2.82, p=0.0042, Mean Difference 2.54 SEM 0.88, 95% Confidence
Intervals (CI) 0.81, 4.28, Cohen's D 0.24). There was also statisticallya significant
benefits in agitation (CMAI Z score 2.68 p=0.0076, Mean Difference 4.27 SEM 1.59,
95% CI -7.39, -1.15, Cohen's D 0.23) and in overall neuropsychiatric symptoms (Z
score 3.52 Mean Difference 4.55 SEM 1.28 p=0.00045, 95% CI -7.07,-2.02, Cohen's D
0.30). The benefits were greatest in people with moderate-moderately severe
dementia. There was also a statistically significant benefit in positive care interactions
as measured by QUIS (19.7% increase, SEM 8.94, 95% CI 2.12, 37.16, Cohen's D
0.55, P=0.03). There were no statistically significant differences between the WHELD
intervention and treatment as usual for the other secondary outcomes. A sensitivity
analysis using a pre-specified imputation model confirmed statistically significant
benefits in DEMQOL proxy, and CMAI and NPI with the WHELD intervention compared
to treatment as usual. Antipsychotic drug prescribing was at a low stable level in both
treatment groups across the study and the WHELD treatment intervention did not
reduce antipsychotic use. The WHELD intervention reduced cost compared to
treatment as usual, and the benefits achieved were therefore associated with a cost
saving. The main limitation was that antipsychotic review was based on augmenting
processes within care homes to trigger medical review and did not in this study involve
proactive primary care education. The high mortality rate leading to non-completion in
a significant proportion of participants leads to interpretation challenges for this study
and for all long term intervention studies in nursing homes.
Conclusions
These findings suggest that this staff training and non-pharmacological intervention for
people with dementia living in nursing homes may be able to achieve benefits to QoL,
agitation  and neuropsychiatric symptoms, as well as cost saving in a model that can
readily be implemented into nursing homes. The benefits in QoL, agitation and
neuropsychiatric symptoms had a small effect size.  The benefits to agitation and
neuropsychiatric symptoms are comparable to (agitation) or better than (NPI) the
benefits seen with antipsychotic drugs.  Importantly, the benefits were achieved in the
context of a cost saving and used a model that can readily be implemented into
nursing homes.
Suggested Reviewers: Dawn Brooker
University of Worcester
dawn.booker@worc.ac.uk
Alistair Burns
University of Manchester
alistair.burns@manchester.ac.uk
Opposed Reviewers:
Additional Information:
Question Response
Financial Disclosure
Please describe all sources of funding
This research was funded by the National Institute of Health Research, Programme
Grant for Applied Research (Ref: RP-PG-0608-10133).
https://www.nihr.ac.uk/funding-and-support/funding-for-research-studies/funding-
programmes/programme-grants-for-applied-research/
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
that have supported your work. This
information is required for submission and
will be published with your article, should
it be accepted. A complete funding
statement should do the following:
Include grant numbers and the URLs of
any funder's website. Use the full name,
not acronyms, of funding institutions, and
use initials to identify authors who
received the funding.
Describe the role of any sponsors or
funders in the study design, data
collection and analysis, decision to
publish, or preparation of the manuscript.
If the funders had no role in any of the
above, include this sentence at the end of
your statement: "The funders had no role
in study design, data collection and
analysis, decision to publish, or
preparation of the manuscript."
However, if the study was unfunded,
please provide a statement that clearly
indicates this, for example: "The author(s)
received no specific funding for this work."
* typeset
The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests
You are responsible for recognizing and
disclosing on behalf of all authors any
competing interest that could be
perceived to bias their work,
acknowledging all financial support and
any other relevant financial or non-
financial competing interests. You will be
able to provide a separate, individual
declaration concerning only your own
competing interests further down in this
form.
Do any authors of this manuscript have
competing interests (as described in the
PLOS Policy on Declaration and
Evaluation of Competing Interests)?
If yes, please provide details about any
and all competing interests in the box
below. Your response should begin with
this statement: I have read the journal's
policy and the authors of this manuscript
have the following competing interests:
I have read the journal's policy and the authors of this manuscript have the following
competing interest: CB reports grants and personal fees from Acadia pharmaceutical
company, grants and personal fees from Lundbeck pharmaceutical company, personal
fees from Napp pharmaceutical company, personal fees from Roche pharmaceutical
company, personal fees from Orion pharmaceutical company, personal fees from Bial
pharmaceutical company, personal fees from Bristol Myer Squibb pharmaceutical
company, personal fees from Otusaka pharmaceutical company, personal fees from
Novartis pharmaceutical company, personal feees from Sunovion, outside the
submitted work; AC reports personal fees from Lundbeck, personal fees from Novartis,
personal fees from Bial, personal fees from Acadia, personal fees from Sunovion,
outside the submitted work; MO, JF, JW, EMC, BW, AC and CB report grants from
NIHR, during the conduct of the study. All other authors have nothing to disclose.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
If no authors have any competing
interests to declare, please enter this
statement in the box: "The authors have
declared that no competing interests
exist."
* typeset
Data Availability
PLOS journals require authors to make all
data underlying the findings described in
their manuscript fully available, without
restriction and from the time of
publication, with only rare exceptions to
address legal and ethical concerns (see
the PLOS Data Policy and FAQ for further
details). When submitting a manuscript,
authors must provide a Data Availability
Statement that describes where the data
underlying their manuscript can be found.
Your answers to the following constitute
your statement about data availability and
will be included with the article in the
event of publication. Please note that
simply stating ‘data available on request
from the author’ is not acceptable. If,
however, your data are only available
upon request from the author(s), you must
answer “No” to the first question below,
and explain your exceptional situation in
the text box provided.
Do the authors confirm that all data
underlying the findings described in their
manuscript are fully available without
restriction?
Yes - all data are fully available without restriction
Please describe where your data may be
found, writing in full sentences. Your
answers should be entered into the box
below and will be published in the form
you provide them, if your manuscript is
accepted. If you are copying our sample
text below, please ensure you replace any
instances of XXX with the appropriate
details.
If your data are all contained within the
paper and/or Supporting Information files,
please state this in your answer below.
All data are deposited in the Dryad repository:
http://dx.doi.org/10.5061/dryad.j512f21p"
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
For example, “All relevant data are within
the paper and its Supporting Information
files.”
If your data are held or will be held in a
public repository, include URLs,
accession numbers or DOIs. For example,
“All XXX files are available from the XXX
database (accession number(s) XXX,
XXX)." If this information will only be
available after acceptance, please
indicate this by ticking the box below.
If neither of these applies but you are able
to provide details of access elsewhere,
with or without limitations, please do so in
the box below. For example:
“Data are available from the XXX
Institutional Data Access / Ethics
Committee for researchers who meet the
criteria for access to confidential data.”
“Data are from the XXX study whose
authors may be contacted at XXX.”
* typeset
Additional data availability information: Tick here if the URLs/accession numbers/DOIs will be available only after acceptance
of the manuscript for publication so that we can ensure their inclusion before
publication.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1 
 
Impact of person-centered care training and person-centered activities on quality of life, 1 
agitation and antipsychotic use in people with dementia living in nursing homes: A cluster-2 
randomized controlled trial  3 
 4 
Clive Ballard1†*, Anne Corbett†2, Martin Orrell3, Gareth Williams4, Esme Moniz-Cook5, Renee 5 
Romeo6, Bob Woods7, Lucy Garrod8, Ingelin Testad9, Barbara Woodward-Carlton10, Jennifer 6 
Wenborn11, Martin Knapp12, Jane Fossey13  7 
 8 
1 Executive Dean & Pro-Vice-Chancellor, Exeter University Medical School, Exeter University, 9 
Exeter, UK 10 
2 Senior Lecturer in Dementia Research, Exeter University Medical School, Exeter University, 11 
Exeter, UK a.m.j.corbett@exeter.ac.uk 12 
3 Director, Institute of Mental Health and Head of Division of Psychiatry and Applied 13 
Psychology, Institute of Mental Health, University of Nottingham UK 14 
4 Bioinformatics Officer, Wolfson Centre for Age-Related Diseases, King’s College London, 15 
London, UK 16 
5 Professor of Clinical Psychology, Faculty of Health and Social Sciences, University of Hull, 17 
Hull, UK 18 
6 Programme Manager, Oxford Health NHS Foundation Trust, Oxford,UK 19 
7 Professor of Clinical Psychology of the Elderly, DSDC Wales, Bangor University, Bangor, UK 20 
8 Research Therapist, Oxford Health NHS Foundation Trust, Oxford, UK 21 
9 Clinical Trials Portfolio Lead, Wolfson Centre for Age-Related Diseases, King’s College 22 
London, London, UK 23 
10 Research Network Volunteer, Alzheimer’s Society, London, UK 24 
Manuscript Click here to download Manuscript
Ballard_WHELD_Manuscript_Clean
2 
 
11 Programme Manager, Division of Psychiatry, University College London / R&D Department, 25 
London, UK 26 
12 Professor of Health Economics, London School of Economics 27 
13Associate Director of Psychological Services, Oxford Health NHS Foundation Trust, Oxford, 28 
UK 29 
 30 
†Joint First Author 31 
*Corresponding author: c.ballard@exeter.ac.uk; Exeter University Medical School, Heavitree 32 
Road, Exeter EX1 2LU 33 
Email: c.ballard@exeter.ac.uk 34 
Phone: 01392 722911 35 
 36 
Short Title: Impact of the WHELD intervention on quality of life in dementia 37 
Word Count: 5607 38 
Trial Registration: ISRCTN; Ref: ISRCTN62237498 39 
 40 
URL: http://www.isrctn.com/ ISRCTN62237498 41 
 42 
 43 
 44 
 45 
 46 
Abstract 47 
3 
 
 48 
Background Agitation is a common, challenging symptom affecting large numbers of people 49 
with dementia and impacting on quality of life (QoL). There is an urgent need for evidence-50 
based, cost-effective psychosocial interventions to improve these outcomes, particularly in 51 
the absence of safe, effective pharmacological therapies. This study aimed evaluate the 52 
efficacy of a person-centered care and psychosocial intervention (WHELD) on QoL, agitation 53 
and antipsychotic use in people with dementia living in nursing homes, and to determine its 54 
cost. 55 
Methods and Findings: This was a randomized controlled cluster trial conducted between 1st 56 
January 2013 and 30th September 2015 which compared the WHELD intervention with 57 
treatment as usual in people with dementia living in 69 UK nursing homes, using an intention 58 
to treat analysis. All nursing homes allocated to the intervention received staff training in 59 
person-centered care (PCC), social interaction (SoI) and education regarding antipsychotic 60 
medications (AM) followed by ongoing delivery through a care staff champion model. Primary 61 
outcome measure was QoL (DEMQOL-proxy). Secondary outcomes were agitation (Cohen 62 
Mansfield Agitation Inventory), neuropsychiatric symptoms (NPI), antipsychotic use, global 63 
deterioration (CDR), mood (Cornell Scale for Depression in Dementia CSSD), unmet needs 64 
(Camberwell Assessment of Need in the Elderly CANE), mortality, quality of interactions 65 
(Quality of Interactions Scale –QUIS), pain (Abbey) and cost. Costs were calculated using cost 66 
function figures compared with usual costs. 847 people were randomized to WHELD or 67 
treatment as usual, of whom 553 completed the nine-month RCT. The intervention conferred 68 
a statistically significant improvement in QoL (DEMQOL proxy z score 2.82, p=0.0042, Mean 69 
Difference 2.54 SEM 0.88, 95% Confidence Intervals (CI) 0.81, 4.28, Cohen’s D Effect Size 70 
0.24). There were also statistically significant benefits in agitation (CMAI Z score 2.68 71 
4 
 
p=0.0076, Mean Difference 4.27 SEM 1.59, 95% CI -7.39, -1.15, Cohen’s D 0.23) and overall 72 
neuropsychiatric symptoms (Z score 3.52 Mean Difference 4.55 SEM 1.28 p=0.00045, 95% CI 73 
-7.07,-2.02, Effect Size 0.30). Benefits were greatest in people with moderate-moderately 74 
severe dementia. There was a statistically significant benefit in positive care interactions as 75 
measured by QUIS (19.7% increase, SEM 8.94, 95% CI 2.12, 37.16, Cohen’s D 0.55, P=0.03). 76 
There were no statistically significant differences between WHELD and treatment as usual for 77 
the other outcomes. A sensitivity analysis using a pre-specified imputation model confirmed 78 
statistically significant benefits in DEMQOL proxy, CMAI and NPI with the WHELD 79 
intervention. Antipsychotic drug prescribing was at a low stable level in both treatment 80 
groups and the intervention did not reduce use. The WHELD intervention reduced cost 81 
compared to treatment as usual, and the benefits achieved were therefore associated with a 82 
cost saving. The main limitation was that antipsychotic review was based on augmenting 83 
processes within care homes to trigger medical review and did not in this study involve 84 
proactive primary care education. An additional limitation was the inherent challenge of 85 
assessing QoL in this patient group. 86 
 87 
Conclusions  88 
These findings suggest that the WHELD intervention confers benefits to QoL, agitation and 89 
neuropsychiatric symptoms, albeit with relatively small effect sizes, as well as cost saving in a 90 
model that can readily be implemented into nursing homes. Future work should consider how 91 
to facilitate sustainability of the intervention in these settings.  92 
 93 
Trial Registration: ISRCTN62237498 94 
 95 
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Author Summary 96 
Why was this study done?   97 
 People with dementia living in care homes often experience agitation and other 98 
symptoms which are difficult to treat and distressing for the individual.  99 
 100 
What did the researchers do and find?  101 
 We tested the WHELD programme, which combined staff training, social interaction 102 
and guidance on use of antipsychotic medications, in 69 UK care homes in a none-103 
month clinical trial.  104 
 We showed that care homes receiving the WHELD programme saw improvements in 105 
quality of life as well as other important symptoms including agitation, behavior and 106 
pain in people with dementia.  107 
 The WHELD programme was also shown to be cost-effective. 108 
 109 
What do these findings mean?  110 
 The findings show that the WHELD approach is beneficial for people with dementia 111 
living in care homes 112 
 WHELD could be provided in an affordable way to improve the lives of these 113 
individuals, who often do not receive the care they need. 114 
 115 
 116 
 117 
Introduction  118 
 119 
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There are 46.8 million people with dementia worldwide, many of whom reside in nursing 120 
homes. In the UK one third of people with dementia live in care homes [1] and in the US 64% 121 
of people receiving Medicare in nursing homes have dementia [2], demonstrating the 122 
international impact of the condition. The majority of these individuals have moderate or 123 
severe dementia and have highly complex care needs resulting from a combination of 124 
cognitive, functional and communication impairments, neuropsychiatric symptoms and 125 
medical comorbidity, all of which combine to impact on quality of life (QoL). Interventions to 126 
promote QoL in dementia are limited in the literature, and few trials have examined impact 127 
on this important outcome. Despite the close link to agitation and other neuropsychiatric 128 
symptoms, risk of falls, worsening cognition and mortality, none of the 18 randomised 129 
controlled trials of antipsychotic medication have measured QoL as an outcome [3,4]. There 130 
is considerable potential for non-drug approaches to address major drivers of QoL, and a 131 
recent systematic review particularly highlighted the benefit conferred by social interaction 132 
and pleasant activities on both agitation and antipsychotic use [5]. To date interventions to 133 
promote person-centered care have not achieved a significant improvement in QoL for people 134 
with dementia [6-8]. The exception is a recently published intensive proof-of-concept study 135 
which confrmed the added benefits of combining person-centred care training for care staff, 136 
antipsychotic review and social interaction (the WHELD intervention) and demonstrated 137 
significant benefits in QoL, as well as a significant reduction in antipsychotic use [9]. 138 
  139 
Neuropsychiatric symptoms affect 90% of people at some point during the course of their 140 
condition [10]. Agitation, frequently including aggression, is particularly common amongst 141 
those with moderate to severe dementia living in nursing homes, where the cross-sectional 142 
prevalence of these symptoms exceeds 50% [11]. Agitation is associated with increased 143 
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distress to residents and a burden to family and professional caregivers [4] and is one of the 144 
most challenging symptoms for clinical management. Importantly, agitation is closely 145 
associated with reduced QoL in people with dementia. There is evidence to support modest 146 
benefits of antipsychotic treatment for some symptoms of agitation, particularly risperidone, 147 
olanzapine and aripiprazole for the short-term management of severe aggression. The 148 
benefits on other symptoms of agitation and with longer term treatment are less clear [12-149 
15]. Moreover, antipsychotics are associated with severe safety concerns including increased 150 
cognitive decline, stroke and death, particularly when used in the long term [13,15-17]. Best 151 
practice guidance emphasises the importance of frequent monitoring and judicious 152 
prescribing in order to reduce these risks, but also to ensure identification of situations where 153 
antipsychotic use is warranted [18,19]. Recent studies also highlight emerging 154 
pharmacological alternatives to antipsychotic medications. The CitAD trial examined 155 
treatment with citalopram for nine weeks in 186 people with AD, reporting significant 156 
reduction in agitation (Odds Ratio 2.13, p=0.01) and caregiver distress [20], and a trial of 157 
dextromethorphan-quinidine in 194 people with AD reported clinically relevant benefit to 158 
agitation (ordinary least squares z statistic: -3.95, p<0.001) over a ten week treatment period 159 
[21]. Whilst this emerging evidence base is promising, there were safety concerns with 160 
citalopram and both studies only evaluated relatively short term therapy over 10 weeks. 161 
There is also currently a lack of evidence supporting sustained benefit for any current 162 
pharmacological treatment for agitation.  163 
 164 
Livingston and colleagues (22) in a comprehensive sytematic review examined the benefits of 165 
a range of sensory, psychological and behavioural interventions in the treatment of agitation.  166 
The authors identified 160 clinical trials and reported promising indications of benefit across 167 
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a range of interventions. A parallel systematic review concentrating specifically on 168 
psychological and behavioural interventions identified 40 clinical trials in people with 169 
dementia, highlighting in particular the potential value of enjoyable acitivites as a successful 170 
treatment approach for agitation (5).  A more specifc systematic review and meta-analysis 171 
concentrating on parallel group clinical trials of dementia related person centred care training 172 
identified 5 trials. A meta-analysis of these studies demonstrated significant benefits in the 173 
treatment of agitation and in achieving reductions in the use of antipsychotic medications.  174 
No significant benefits in improving quality of life were however achieved (8). This literature 175 
highlights the growing evidence-base to support the value of person-centered care and non-176 
pharmacological interventions for the management of agitation and reduction in 177 
antipsychotic use for people with dementia in nursing homes, which was further augmented 178 
by a recently published WHELD factorial intervention [6-8,22-24].  179 
 180 
Cost is a major consideration in the development and implementation of interventions in 181 
nursing homes [5,8,9,22,23]. None of the evidence-based interventions to promote PCC have 182 
been widely adopted in clinical and care practice, and this is likely due in part to a lack of 183 
robust evidence regarding the cost profile of these approaches. A potentially cost-effective, 184 
practical means of overcoming this issue is to deliver interventions through a Champions 185 
model, enabling care staff to take ownership for ongoing implementation in the home, with 186 
more limited supervision from external therapists. 187 
 188 
The goal of this RCT is to evaluate the impact of the WHELD intervention on QoL, agitation, 189 
neuropsychiatric symptoms, antipsychotic reduction and cost in comparison to treatment as 190 
usual. 191 
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 192 
Methods 193 
 194 
Study design 195 
This study was a nine month cluster-randomized controlled two-arm trial conducted in 69 UK 196 
nursing homes between 1st January 2013 and 30th September 2015. There were three 197 
recruiting hubs based in South London, North London and Buckinghamshire. Each cluster was 198 
randomized to receive either the WHELD intervention or treatment as usual for nine months. 199 
This research was reviewed and approved by the Oxford C National Research Ethics 200 
Committee (Ref: 13/SC/0281). This study is registered with the ISRCTN database (Ref: 201 
ISRCTN62237498). The full protocol is available in the published protocol paper [25]. 202 
 203 
Eligibility criteria 204 
Eligible nursing homes had at least 60% of residents with dementia. Nursing homes were 205 
excluded if they were receiving special support from their local authority or if they failed to 206 
meet the five Care Quality Commission care home quality standards. Within each 207 
participating nursing home all residents were considered potentially eligible for inclusion if 208 
they met criteria for dementia (defined as a score ‘1’ or greater on the CDR [26], 209 
operationalized to require a minimum level of cognitive, functional and neuropsychiatric 210 
features). 211 
 212 
Interventions 213 
The WHELD intervention consisted of a combination of elements taken from the interventions 214 
evaluated in a previous proof-of-concept study [9]. The intervention focused on training in 215 
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person-centered care for care staff and on promoting tailored person-centered activities and 216 
social interactions. The intervention also involved the development of a system for triggering 217 
appropriate review of antipsychotic medications by the prescribing physician attached to 218 
each home. 219 
 220 
Training for staff was provided by a research therapist. Two lead care staff members (WHELD 221 
Champions) were nominated in each care home. These individuals received additional 222 
training over a period of four months (one training day per month) with further coaching, 223 
supervision and regular review with the therapist over the nine-month period. The WHELD 224 
Champions were responsible for the delivery and dissemination of the intervention in each 225 
care home. In addition, prescribing physicians were provided with educational materials 226 
about the intervention. The control group received treatment as usual (TAU).  The WHELD 227 
intervention is described in more detail in Box 1 and supplementary table 1. 228 
 229 
Box 1  Details of WHELD intervention 230 
ORIENTATION PHASE 
 
Duration: 2 whole days or 4 half days in each home over 1 month 
 
Delivered by : 1 full time WHELD therapist for each 9 care homes 
Participants: WHELD Therapist meeting with care home managers, staff teams, Dementia 
Champions, residents 
Aim: For WHELD therapist to meet residents and staff to introduce the project and 
provide information arsing since the launch event, meet nominated Dementia Champions 
understand staff hopes and concerns, the layout and facilities of the home where the 
intervention will take place. 
11 
 
 
 
INTERVENTION DELIVERY PHASE 
Duration: 8 months (months 2-9) 
 
Months 2-5:  1 day (6 hours) per month for each care home. Training delivered to 
dementia champions off-site from the care home where they work. 
Delivered by: WHELD Therapist 
Participants: Dementia Champions from care homes 
Aims: 
Day 1: Understanding what person centred care (PCC) is and how homes can apply 
this in the care of residents. Developing ways to share this information with 
colleagues within the home 
Day 2: Writing strengths based Care Plans and providing tailored structured social           
activities which recognise people’s abilities and interests with aim of providing 60 
minutes per week per person. 
Day 3:Understanding the evidence about the use of antipsychotic medication and 
familiarisation with best practice guidelines and considering ways homes could work 
with their local GPs to use this 
 
Day 4: Developing ways to understand the individual needs of people who are 
distressed (sometimes referred to as “challenging behaviour”) using a formulation of 
need based model  and identifying ways  of using information gained through PCC/ 
care planning (sessions 1 and 2) to meet the needs. 
 
Delivery Style :All sessions were manualised and involved: didactic sessions, experiential  
learning, individual goal setting for  each home for dissemination of training information 
and implementation activities between training sessions 
 
Months 6-9:  On –site consultation sessions totalling 8 hours per month with each care 
home. Delivered flexibly, by negotiation, to best support each homes’ needs. 
 
CONCURRENTLY  
12 
 
 
Months 2-9: Cascade training and implementation of activities 
Training Delivered by: Dementia Champions  
Activities developed by:  Dementia Champions and staff team members 
Delivery Style: Adapted for care setting involved standalone training sessions, modelling 
skills, incorporating sessions into daily routine, working with individual residents to 
develop personalised and tailored activities for 60 minutes a week , care home team 
formulation and medication review  and goal planning sessions to influence care planning. 
 231 
 232 
Outcome Measures 233 
All participants were assessed for dementia severity at baseline using the CDR [26], a 234 
validated scale used to quantify the severity of dementia using a structured interview, and 235 
the Functional Assessment Staging Tool (FAST) [27], a validated functional ordinal assessment 236 
scale of elderly people with dementia. 237 
 238 
All outcome measures were assessed prior to randomization and after nine months of the 239 
intervention by a trained research assistant.  The assessments at follow-up were collected by 240 
research assistants who had not previously visited the participating care homes.  The research 241 
assistants were blind to treatment allocation, and every effort was made to maintain the blind 242 
by minimizing contact between the research assistants and research therapists, ensuring that 243 
dementia champions were not informants and clear instructions to care homes and the 244 
research team to not disclose treatment allocation. The primary outcome was QoL, measured 245 
by the DEMQOL proxy [28], a 31-item interviewer-administered questionnaire answered by a 246 
caregiver with a score range of 31 to 124 which assesses the QoL for people with dementia.  247 
 248 
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The secondary outcome measures were agitation and other neuropsychiatric symptoms, 249 
assessed using the Cohen-Mansfield Agitation Inventory (CMAI) [29], a caregiver 250 
questionnaire of agitation completed through an interview with the caregiver, consisting of 251 
29 items, each of which is rated on a seven-point scale of frequency. Information regarding 252 
antipsychotic use and the use of other psychotropic medications was recorded from 253 
medication charts. Overall neuropsychiatric symptoms were assessed with the 254 
Neuropsychiatric Inventory (NPI – nursing home version) The NPI-NH [30,31] was developed 255 
to assess psychopathology in patients with dementia in nursing homes and evaluates 12 256 
neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, 257 
dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behaviour, 258 
night-time behaviour disturbances, and appetite and eating abnormalities. The score of each 259 
item, if present, represents the product of symptom frequency and severity, with a maximum 260 
score of 12 for each domain. Secondary outcomes also included global deterioration 261 
(CDR)[26], mood (Cornell Scale for Depression in Dementia CSSD) [32], antipsychotic use, 262 
unmet needs (Camberwell Assessment of Need in the Elderly –CANE)[33], quality of 263 
interactions (Quality of Interactions Scale –QUIS)[34], pain (Abbey Pain Scale)[35], mortality 264 
and cost.  265 
 266 
Economic data for each individual in the study were collected using an adapted version of the 267 
Client Service Receipt Inventory (CSRI) [36,37] which includes questions about the individual’s 268 
sociodemographic profile, care home charges, and use of health and social care services. In 269 
addition, the staffing inputs of the optimized intervention were measured and covered time 270 
spent by the therapist and champion in training, supervision and preparation.  271 
 272 
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Randomization and Blinding 273 
Nursing homes were allocated to receive either the WHELD intervention or treatment as usual 274 
(TAU) using secure web access to the remote randomization centre at North Wales 275 
Organization for Randomized Trials in Health Clinical Trial Unit (NWORTH CTU) at Bangor 276 
University. Randomization was performed by dynamic allocation [38] to protect against 277 
subversion while ensuring that the trial maintained a good balance to the allocation ratio of 278 
1:1 both within each stratification variable and across the trial. Nursing homes were stratified 279 
by region and size. The system has been coded and validated in the R statistical package. The 280 
NWORTH CTU generated randomization codes and assigned clusters to intervention groups.  281 
This information was passed to the trial manager, and only passed on to the PI for each site 282 
once all baseline evaluations had been completed. 283 
 284 
Individual baseline participants were consented and evaluated prior to randomization to 285 
minimize bias. Written consent was provided by participants when the individual had mental 286 
capacity to provide consent for their own participation.  Written consent was provided by 287 
next of kin when individuals did not have mental capacity to consent for themselves. Clinicians 288 
and research assistants completing follow-up assessments were blind to treatment allocation. 289 
Every attempt was made to minimize accidental un-blinding by minimizing contact between 290 
therapists and the researchers collecting outcome data and with clear instructions to 291 
researchers and nursing home staff to not discuss treatment allocation.  292 
 293 
Sample size 294 
The target minimum sample size was 640 at the nine-month time point. Previous studies 295 
indicate that intra-home correlation coefficients rarely exceed 0.05. Taking this into account, 296 
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a sample size of 640 participants therefore gives 90% power using a significance level of 5% 297 
to detect a standardized effect size of 0.3 SDs, which is generally accepted as the lowest 298 
threshold of a clinically meaningful benefit. The recruitment of a minimum of 840 participants 299 
allowed for loss of 200 through mortality or withdrawal, an important consideration in the 300 
context of the high morbidity and mortality of this group. 301 
 302 
Data Analysis 303 
Outcome measures for the study were assessed at baseline and at nine months. All the 304 
outcome measures collected were described and reported using appropriate descriptive 305 
statistics and tabular and graphical techniques. Means with 95% confidence intervals were 306 
quoted and a 5% significance level was reported. The Consolidated Standards of Reporting 307 
Trials (CONSORT) diagram information is presented in order to identify any differential 308 
dropout between the arms of the trial.  The analysis of the quantitative outcomes was 309 
undertaken using a multilevel analysis of covariance (ANCOVA). 310 
 311 
The primary outcome measure (DEMQOL proxy) and the secondary outcome measures were 312 
analysed using the multilevel modelling approach to ANCOVA, with the value at nine months 313 
as the response. The baseline value was the covariate. The key factor was group (treatment 314 
(WHELD or control –Treatment as Usual). The multilevel nature of the design was represented 315 
by two levels: care home and individual residents in the care home. Other covariates were 316 
number of residents in each cluster and the age, gender and severity of dementia (FAST stage 317 
–baseline and follow-up) of participants with dementia.  The provisional analysis plan was 318 
developed based on the analysis model developed for a previous smaller factorial study of 319 
the WHELD intervention (9). In addition to the standard ANCOVA model, this included work 320 
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to model and identify the best model for the inclusion of baseline co-variates and evaluation 321 
of several imputation models. The same baseline covariate model was used in the final 322 
analysis plan for the current study. The imputation model was less predictive in validation 323 
analyses than it had been in the factorial study. The completer analysis was therefore 324 
analysed as the primary outcome in place of the imputation analysis. Therefore the primary 325 
analysis included all participants with data available at the nine month assessment point, and 326 
the imputation model was used as a sensitivity analyses.  The analysis model was finalized 327 
prior to the locking of the study database for the current trial.   328 
 329 
 330 
The same approach was used for the analysis of all secondary outcomes other than mortality, 331 
antipsychotic use, QUIS and cost. CMAI and antipsychotic use, except that baseline CMAI and 332 
baseline antipsychotic use were used as covariates rather than baseline DEMQOL proxy. 333 
 334 
Mortality and antipsychotic use were compared between treatment groups using Relative 335 
Risk with 95% CI.  QUIS used care home level data, and was compared between treatment 336 
groups using ANCOVA, but because of the smaller sample size did not use baseline covariates. 337 
 338 
Further exploratory sub-group analysis were undertaken evaluating differences between 339 
WHELD and treatment as usual in people with mild-moderate, moderately severe and severe 340 
dementia respectively based on the recommendations of the reviewers as part of the journal 341 
submission process.  Based on these recommendations effect sizes and Number Needed to 342 
Treat were also evaluated.    343 
 344 
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Cost analysis  345 
Total costs for each participant were derived from the collection of service use data for the 346 
three month period prior to the intervention (baseline) and the nine months of the 347 
intervention (follow-up) and consisted of three main cost categories: intervention costs, 348 
accommodation charges and health and social care costs. Intervention costs were calculated 349 
by deriving average hourly costs for WHELD Champions and therapists, combined with time 350 
spent by each staff type on training, supervision and intervention delivery, and defined as a 351 
per participant cost. An additional cost was defined for the AR element intervention for 352 
participants receiving antipsychotics. Accommodation costs were collected as weekly charges 353 
for each nursing home. Where this was unavailable or not known the typical charge for a 354 
resident with similar level of need to the participant in the study was obtained. Total health 355 
and social care costs consisted of services that are the main contributors to the cost of care 356 
in nursing homes: hospital inpatient, outpatient, day hospital, accident and emergency 357 
services, primary care (calculated as per minute unit costs for GPs and Practice Nurses), 358 
community health care and ambulatory care. Data on each nursing home resident’s use of 359 
health care (obtained from the CSRI) were multiplied by appropriate unit costs to calculate 360 
health and social care costs for each participant at each time point. Mean differences in costs 361 
and 95% CIs were obtained by non-parametric bootstrapped regression (1000 repetitions) 362 
modeling to account for non-normal distributions. A multilevel mixed model was used, 363 
controlling for site and age at entry into the study. The adjusted total health and social care 364 
cost and outcomes models also included the treatment variable as a random effect at the care 365 
home level. Clustering was accounted for by allowing the model intercept and treatment 366 
variable coefficient (i.e. treatment effect) to vary by care home.  367 
 368 
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Sensitivity Analysis 369 
 370 
As a sensitivity analysis, the same analysis was undertaken for the primary and key secondary 371 
outcomes but using imputed values for people who did not complete the nine month follow-372 
up.  Logistic regression was used to predict missing variables from the factors and covariates 373 
measured at baseline, using the approach validated in a previous factorial study [39]. 374 
 375 
Data deposited in the Dryad repository: http://dx.doi.org/10.5061/dryad.j512f21p[40]. 376 
 377 
Results 378 
 379 
Cohort characteristics 380 
1006 participants were consented to the study, with 847 individuals randomized to TAU or 381 
WHELD. The majority of participants had moderately severe or severe dementia and 71% 382 
were female. Follow-up assessments were available for 553 participants. Mortality accounted 383 
for the majority of participants who did not complete follow up assessments. The descriptive 384 
statistics for participants who completed the follow up were similar to the original population, 385 
although numerically marginally more residents receiving TAU completed the follow up 386 
compared to those on WHELD intervention (66.8% vs. 63.6%). The baseline characteristics of 387 
the study participants are described in Table 1 and flow of participants through the study is 388 
presented in Figure 1. The trial ended after the last follow-up assessment of the last 389 
participant was completed. 390 
 391 
Table 1 Descriptive statistics for baseline cohort and completers 392 
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 Baseline cohort 
(n = 847) 
Completers 
(n = 553) 
 TAU 
 
WHELD 
 
TAU 
 
WHELD 
 
Total N (%) 443 
(100) 
404 
(100) 
296 
(66.82) 
257 
(63.61) 
Sex 
Male N (%) 129 
(29.1) 
132 
(32.7) 
84  
(28.4) 
78 
(30.4) 
Female N 
(%) 
314 
(70.9) 
272 
(67.3) 
212 
(71.6) 
179 
(69.6) 
Age (Mean, 
SEM) 
88,5 
(0.50) 
88,4 
(0.57) 
86.6 
(0.50) 
86.6 
(0.53) 
FAST Score 
Mild 
dementia or 
less N (%) 
35 
(7.90) 
47 
(11.64) 
21 (7.09) 23 
(8.95) 
Moderate 
dementia N 
(%) 
38 
(8.58) 
39 
(9.65) 
15 
(5.07) 
16 
(6.22) 
Moderately 
severe 
dementia N 
(%) 
267 
(60.27) 
241 
(59.65) 
159 
(53.71) 
153 
(59.53) 
Severe 
dementia (N 
(%)  
103 
(23.23) 
77 
(19.06) 
101 
(34.12) 
65 
(25.29) 
Antipsychotic Use 
Yes N (%) 78 
(9.2%) 
75 
(8.9%) 
51 
(9.2%) 
52 
(9.4%) 
 DEMQOL-
Proxy score 
Mean (SEM) 
103.84 
(0.70) 
103.04 
(0.74) 
103.69 
(0.68) 
105.62 
(0.59) 
CMAI 
Mean (SEM) 
48.49 
(1.03) 
48.29 
(1.04) 
48.1 
(1.06) 
46.0 
(1.01) 
NPI  
Mean (SEM) 
2.13 
(0.13) 
2.36 
(0.23) 
2.14 
(0.14) 
2.33 
(0.24) 
TAU – Treatment As Usual; FAST – Functional Assessment Staging; DEMQOL – Dementia 393 
Quality of Life Scale; CMAI – Cohen-Mansfield Agitation Inventory; NPI – Neuropsychiatric 394 
Inventory; SEM – Standard Error of Mean 395 
 396 
Figure 1 CONSORT Chart showing flow of participants through the study 397 
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 398 
Outcome Measures  399 
The WHELD intervention conferred a statistically significant 2.54 (SEM 0.88) point 400 
improvement in QoL compared to TAU (95% Confidence Intervals (CI) 0.81, 4.28, Cohen’s D 401 
0.24).as measured by the DEMQOL-proxy compared to TAU over nine months (z score 2.82, 402 
Mean Difference 2.54 SEM 0.88 p=0.0042). On the secondary outcomes, WHELD also 403 
conferred a statistically significant 4.27 (95% CI -7.39, -1.15, Cohen’s D 0.23, Z score 2.68 404 
Mean Difference 4.27 SEM 1.59 p=0.0076) point benefit on the CMAI compared to TAU with 405 
respect to agitation and conferred a statistically significant 4.55 (95% CI -7.07,-2.02, Cohen’s 406 
D 0.30 , Z score 3.52 Mean Difference 4.55 SEM 1.28 p=0.00045)  point benefit on the total 407 
NPI NH compared to TAU with respect to overall neuropsychiatric symptoms. The multilevel 408 
mixed-effects linear or logistic regression models for primary and secondary outcome 409 
measures are shown in Table 2. 410 
 411 
Table 2 Effect estimates of WHELD intervention in comparison to TAU on primary outcome 412 
and key secondary outcome measures (Multiple Imputation Analysis) 413 
Outcome 
Measure 
Adj. 
Effect 
(SE)* 
p Mean 
Difference 
(SEM) 
95% 
Confidence 
Intervals of 
mean 
difference 
Effect Size 
(Cohen’s D) 
Number 
Needed to 
Treat∆ 
DEMQOL-
Proxy 
(n=553) 
R=0.12 
Z=2.82  
0.0042 2.54+ (0.88) 0.81, 4.28 0.24 9 
CMAI 
(n=553) 
R – 
0.11 
Z = 
2.68 
0.0076 4.27+ (1.59) -7.39, -1.15 0.23 6 
NPI 
(n=547) 
R=-1.5 
Z=3.52 
0.00045 4.55+ (1.28 -7.07,-2.02               0.30 9 
 414 
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*Adj. effect takes into account baseline value, age, sex, CDR, site, and clustering within care 415 
homes. 416 
∆ based on binary outcome: better than mean overall outcome or mean outcome or worse 417 
than overall mean outcome for DEMQOL and CMAI respectively 418 
+ DemQOL (Dementia Quality of Life Scale): Improvement in WHELD group from baseline to 9 419 
months 4.78, Improvement in DEMQOL in treatment as usual group 2.24, mean difference 420 
2.54 421 
+ CMAI (Cohen-Mansfield Agitation Inventory): Improvement in WHELD group from baseline 422 
to 9 months -4.13, worsening in CMAI in treatment as usual group 0.14, mean difference 4.27 423 
+ NPI NH (Neuropsychiatric Inventory,  Nursing Home version): Improvement in WHELD group 424 
from baseline to 9 months -2.64, worsening in NPI NH in treatment as usual group 1.91, mean 425 
difference 4.55 426 
 427 
 428 
 429 
Prescriptions of antipsychotic medications were stable across the study in both treatment 430 
groups, with no reduction in prescribing in the WHELD treatment group compared to 431 
treatment as usual (Change in Antipsychotic Prescribing: WHELD -0.1% SEM 0.1 , TAU -0.2% 432 
SEM 0.1, P=0.60; antipsychotic prescribing at nine months: WHELD v TAU Relative Risk 1.06, 433 
95% CI 0.62 to 1.82 P=0.82). For other secondary outcomes, there were no statistically 434 
significant differences between the WHELD group and TAU groups for change in global 435 
deterioration (CDR   Z= 0.053 Mean Difference 0.011 SEM 0.22  p=0.96), unmet needs (CANE 436 
Z=0.84  Mean Difference 0.04 SEM 0.08 P=0.62), pain (Abbey Z=1.084 Mean Difference 0.33 437 
SEM 0.31 p=0.27) or mood (CSSD  Z=0.036  mean difference 0.017 SEM 0.48 p=0.97). There 438 
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were no significant interaction effects in the primary analysis model, and further analyses 439 
accounting for interactions were therefore not undertaken. 440 
 441 
The quality of interactions of positive care between care staff and residents with dementia 442 
(QUIS) was collected as a care home level assessment in 62 of the participating care homes.  443 
There was a statistically significant 19.7% increase in the proportion of positive care 444 
interactions (SEM 8.94, 95% CI 2.12, 37.16, Cohen’s D 0.55, P=0.03).   445 
 446 
A sub-group analysis was also undertaken comparing the WHELD intervention in people with 447 
mild-moderate (FAST 4-5), moderately severe (FAST 6) and severe (FAST 7) dementia 448 
respectively focusing on the primary and key secondary outcomes (DEMQOL, CMAI, NPI).  449 
Statistically significant benefits of similar magnitude to the overall benefits were seen in 450 
people with moderately severe dementia for both quality of life, agitation and overall 451 
neuropsychiatric symptoms, but there were no statistically significant benefits on quality of 452 
life in the smaller groups of individuals with mild-moderate or severe dementia.  The full 453 
results are shown in Table 3. 454 
 455 
Table 3 Effect estimates of WHELD intervention in comparison to TAU on key outcome 456 
measures (Multiple Imputation Analysis): Sub-analysis Evaluating impact of WHELD in mild-457 
moderate, moderately severe and severe dementia 458 
 459 
 Adj. Effect 
(SE)* 
p Mean 
Difference 
(SEM) 
95% Confidence 
Intervals of 
mean difference 
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DEMQOL Proxy 
Severe AD R=0.00 
Z=0.03 
0.97 -0.06 (1.72) (-3.43,3.32) 
modsevAD R=0.20 
Z=3.62 
0.0003 4.28 (1.16) (2.01,6.56) 
mildmodAD R=0.06 
Z=0.61 
0.54  1.11(1.83) (-2.47,4.69) 
CMAI 
severeAD R=-0.06 
Z=0.55 
0.58 -2.24 (4.05) (-10.17,5.69) 
modsevAD R=-0.12 
Z=2.08 
0.04 -4.52 (2.17) (-8.77,-0.27) 
mildmodAD R=-0.18 
Z=1.93 
0.05 -4.57 (2.34) (-9.15,0.008) 
NPI 
Severedem R=0.19  
Z=1.91 
0.05 -5.73(2.90) (-11.42,-0.04) 
ModSevdem R=0.15  
Z=2.74 
0.006 -4.83(1.75) (-8.26,-1.387) 
MildModdem R=0.14  
Z=1.54 
0.13 
-3.05(1.99) 
(-6.94,0.84) 
 460 
*Adj. effect takes into account baseline value, age, sex, CDR, site, and clustering within care 461 
homes. 462 
 463 
 464 
 465 
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The sensitivity analysis using imputed values confirmed that WHELD conferred a statistically 466 
significant benefit in DEMQOL proxy (1.5 SEM 0.06 point benefit, Z 2.50, p=0.015), CMAI (1.96 467 
SEM 0.08 point benefit, Z=2.06, p=0.04) and NPI (Mean Difference -2.45 SEM 0.066 Z=2.64 468 
P=0.01) compared to treatment as usual. 469 
 470 
 471 
Adverse Events 472 
A total of 549 Serious Adverse Events were recorded during the period of the trial. The events 473 
were balanced between the two treatment groups with no statistical differences (291 events 474 
in WHELD group and 258 in TAU group – Table 4). There was no significant difference in 475 
mortality between the WHELD and treatment as usual group (Relative Risk 1.08 95% CI 476 
0.86 to 1.35, P = 0.50). 477 
 478 
 479 
Table 4: Serious Adverse Event reporting by category and WHELD treatment group  480 
  Group  
SAE category WHELD TAU TOTAL 
Dehydration 8 2 10 
Fall 30 14 44 
Fractures 15 13 28 
Mortality 122 103 225 
Pneumonia 16 12 28 
Stroke 3 8 11 
Delirium 0 1 1 
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Chest Infections 26 15 41 
Renal 2 1 3 
Increased confusion 4 0 4 
UTI 11 7 18 
Pulmonary embolism 1 0 1 
Other 53 82 135 
Total per group 291 258 549 
 481 
 482 
  483 
 484 
Cost analysis 485 
The direct cost of delivering the intervention compared to TAU was £8,627 per home. 53% 486 
(£4,554) of the cost related to WHELD Champion time spent in training and supervision. The 487 
remaining costs related to therapist time. Delivery of the intervention to residents incurred 488 
an additional £130 per person per month. The additional cost incurred for AR was £23 per 489 
resident, which accounted for Champion time spent reviewing antipsychotic use in 16% of 490 
residents and contacting prescribing physicians. Analysis of service use showed higher 491 
healthcare costs unrelated to the intervention in the TAU group compared to the WHELD 492 
intervention group. Participants receiving the intervention showed a significant health and 493 
social care cost advantage. Taking into account the cost of the intervention and the total 494 
health and social care costs, there was a cost advantage for the WHELD treatment (Table 5). 495 
 496 
 497 
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 498 
Table 5 Unadjusted mean costs and mean cost differences at baseline and over nine months 499 
(£, 2014 – 2015) 500 
 Intervention TAU Intervention vs. TAU^ 
Cost categories Mean 
(£) 
SD  
(£) 
Mean 
(£) 
SD 
 (£) 
Unadjusted 
mean 
difference (£) 
95% CI 
WHELD intervention  2713 121 0 -  2713 (2701 to 2724) 
Baseline (n=887) 
 Accommodation 
charges 
9480 (2010) 10233 (3675) -753 (-1128 to -365) 
 Hospital  387 (1759) 407 (2413) -20 (283 to 242) 
 Primary care 96 (126) 98 (148) -2 (19 to 14) 
 Community health  23 (80) 19 (79) 4 (-7 to 14)  
 Emergency 12 (37) 9 (34) 3 (-1 to 7) 
Total health and 
social care costs 
9998 (2601) 10766 (4396) -768 (-1249 to -338) 
Nine month follow-up (n=553) 
 Accommodation 
charges 
28606 (10863) 33005 (12428) -4399 (-5725 to -2898) 
 Hospital  269 (1166) 262 (1267) 7 (-183 to 188) 
 Primary care  700 (294) 1020 (301) -320 (-364 to -277) 
 Community health  78 (260) 70 (206) 8 (-23 to 44) 
 Emergency  49 (133) 85 (244) -36 (-68 to -10) 
Total health and 
social care costs  
29702 (8774) 34442 (11106) -4740 (-6129 to -3156) 
^ Cost comparisons for nine months include covariates for site, age, baseline CMAI score and baseline value of the same cost variable. 501 
Baseline cost comparisons include covariates for site, age and baseline CMAI score  502 
 503 
 504 
Discussion 505 
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In what is, to our knowledge, the largest RCT conducted of a staff training and non-506 
pharmacological intervention for people with dementia living in nursing homes, we have 507 
demonstrated that the WHELD intervention confers a statistically significant improvement in 508 
QoL over nine months. There was also a statistically significant benefit to agitation and overall 509 
neuropsychiatric symptoms over the nine-month period. Whilst the effect size was small, the 510 
benefits in agitation and neuropsychiatric symptoms are comparable to (agitation) or better 511 
than (NPI) the benefits seen with antipsychotic drugs. There was also a significant increase in 512 
the proportion of positive care interactions between care staff and residents with dementia 513 
with a moderate effect size.  Importantly, the benefits were achieved in the context of a cost 514 
saving and used a model that can readily be implemented into nursing homes. Antipsychotic 515 
drug prescribing was stable in both treatment groups across the study and the WHELD 516 
treatment intervention did not reduce antipsychotic use, albeit from a very low baseline 517 
frequency.  518 
 519 
Despite the importance of QoL few trials have examined impact of interventions on this 520 
outcome, This was, to our knowledge, the largest RCT conducted of a staff training and non-521 
pharmacological intervention for people with dementia living in nursing homes. The WHELD 522 
intervention conferred a statistically significant improvement in QoL over nine months, 523 
building on a previous proof-of-concept study of WHELD. That study reported a reduction in 524 
QoL following antipsychotic review which was mediated by social interaction within the 525 
context of an overall person-centered care training paradigm for care staff [9]. We would 526 
speculate that the added benefit was probably a reflection of the structured approach to 527 
promoting pleasant activities involving social interaction, The optimization of the WHELD 528 
intervention has maintained benefit but reduced overall cost, making it a cost-effective 529 
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program for delivery in care homes. A sub-group analysis focusing on people with mild-530 
moderate, moderately severe and severe dementia indicated that benefits on quality of life 531 
were more robust in people with moderately severe dementia.   532 
 533 
Agitation is a frequent and distressing symptom for people with dementia living in nursing 534 
homes [10,11,41]. Benefits from pharmacological treatment with atypical antipsychotics are 535 
limited to modest improvements in aggression [12,13,15], and the significant advantage on 536 
the CMAI compared to control for the WHELD intervention is comparable with the modest 537 
treatment advantage for atypical antipsychotics from a meta-analysis of previous RCTs 538 
[12,13,15]. In addition, the use of atypical antipsychotics is limited by the significant adverse 539 
effects of these medications in people with dementia [12,13,15]. Although recent studies 540 
have begun to suggest that other pharmacological therapies such as citalopram[20] and 541 
dextromethorphan [21] may confer significant benefit for the treatment of agitation,  but 542 
further studies are needed. There was also a statistically significant benefit in overall 543 
neuropsychiatric symptoms conferred by the WHELD intervention compared to TAU, 544 
suggesting a breadth of benefit beyond just agitation.   545 
 546 
Although comparable to atypical antipsychotics the standardized effects sizes of benefit are 547 
small in the context of a clinical intervention.  The benefits do however also include benefits 548 
in quality of life, which have not been demonstrated with pharmacological interventions.  549 
Although there is no established threshold for a clinically meaningful benefit in quality of life, 550 
any statistically significant benefit is important given the absence of any benefit in previous 551 
studies. In addition, the intervention was not just delivered to a people with clinically 552 
significant neuropsychiatric symptom, but conferred benefit amongst a broader population 553 
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of people with dementia living in care homes.  Whilst the effect size would be considered 554 
marginal in terms of a clinically significant benefit, we believe that the benefits to the broader 555 
population of people with dementia in care homes make this a meaningful benefit in the 556 
quality of care. 557 
 558 
This study is consistent with the evidence base but provides important and novel data within 559 
the literature. Our results also compare favorably to the small number of published 560 
intervention studies which have focused on promoting person-centered care, none of which 561 
have reported benefits to QoL[6,7]. The findings are particularly favorable when compared 562 
with trials of antipsychotic medications which show only very modest benefits over 12 weeks 563 
in the context of significant harms [42,43]. In addition, the current study shows cost-564 
advantages over usual care, which has not been demonstrated with any previous drug or non-565 
drug interventions.  566 
 567 
Elements of the WHELD intervention, such as social interaction and pleasant events, have 568 
previously been demonstrated to improve agitation in modest sized RCTs [22,23]. 569 
Incorporating them within a coherent framework such as WHELD enables straightforward and 570 
affordable implementation of these approaches in clinical and care practice.  571 
 572 
Interestingly, there was a low baseline use of antipsychotic medications (<10%) in this study, 573 
reflecting the major changes in clinical practice and the reductions in antipsychotic use that 574 
have been achieved for people with dementia in the last decade. In contract to our previous 575 
factorial RCT of the WHELD intervention, no significant reduction in antipsychotic use was 576 
achieved and antipsychotic use was stable in both groups. This is likely attributable to a 577 
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combination of the low baseline levels of antipsychotic prescription and the more limited 578 
education program for primary care physicians within the current study than in the previous 579 
factorial RCT, and highlights the potential additional value of primary care education 580 
programs in parallel to care home training.  581 
 582 
This study is a robust well powered RCT evaluating the sustained impact of combining person-583 
centered care and evidence-based non-pharmacological interventions for people with 584 
dementia in nursing homes. The study had good retention of surviving participants compared 585 
to most studies conducted in nursing home settings. The intervention evaluated was 586 
pragmatic, fully manualized and designed so that it can be easily disseminated and 587 
implemented in routine clinical practice. There were also limitations. Antipsychotic review 588 
was based on augmenting processes within care homes to trigger medical review and did not 589 
in this study involve proactive primary care education. In addition, although the study used a 590 
well validated method, evaluating quality of life in people with dementia is challenging and 591 
all methods have some limitations.  High mortality rates are usual in studies of frail groups of 592 
individuals living in care homes, but lead to high non-completion rates and present some 593 
challenges for data analysis and interpretation. One of the original secondary outcomes was 594 
to evaluate the impact of the intervention on the care home environment.  The selected scale 595 
focused mainly on the physical building rather than other aspects of the environment, and 596 
the Program Management Group therefore decided to omit this measure at 9 month follow-597 
up as it was unlikely substantial building renovations had taken place in any of the 598 
participating care homes. 599 
 600 
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A key issue for future studies is the sustainability of the intervention, particularly with 601 
turnover of staff including the dementia champions.  To be sustainable the WHELD 602 
intervention needs to be firmly embedded within the care home culture, and it will be 603 
important for further research to identify the optimal approach to maintain benefits.    As 604 
WHELD is largely verbally based, it will also be important to further evolve interventions more 605 
tailored to the needs of people with more severe dementia. 606 
 607 
 608 
 609 
Acknowledgements 610 
AC and CB thank the National Institute for Health Research (NIHR) Mental Health Biomedical 611 
Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust 612 
and Institute of Psychiatry, King’s College London and the NIHR Collaboration for Leadership 613 
in Applied Health Research and Care South West Peninsula for supporting their time for this 614 
work. The views expressed are those of the author(s) and not necessarily those of the NHS, 615 
the NIHR or the Department of Health. The funder had no role in the design and conduct of 616 
the study, collection, management, analysis, and interpretation of the data and preparation, 617 
review, or approval of the manuscript. 618 
 619 
References 620 
 621 
1. Alzheimer's Disease International. World Alzheimer Report: 622 
http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf 2009 [ 623 
2. Alzheimer's Disease International. World Alzheimer's Report: Journey of Caring, An 624 
analysisof long-term care in dementia 625 
http://www.alz.co.uk/research/WorldAlzheimerReport2013ExecutiveSummary.pdf2013 [ 626 
32 
 
3. Ballard C, Corbett A, Howard R. Prescription of antipsychotics in people with dementiala. 627 
British Journal of Psychiatry. 2014;205(1):4-5. 628 
4. Ballard C, Corbett A. Agitation and aggression in people with Alzheimer's disease. Curr Opin 629 
Psychiatry. 2013;26(3):252-9. 630 
5. Testad I, Corbett A, Aarsland D, Lexow KO, Fossey J, Woods B, et al. The value of 631 
personalized psychosocial interventions to address behavioral and psychological symptoms in 632 
people with dementia living in care home settings: a systematic review. Int Psychogeriatr. 633 
2014;26(7):1083-98. 634 
6. Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged 635 
Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual 636 
care in dementia: a cluster-randomised trial. The Lancet Neurology. 2009;8(4):317-25. 637 
7. Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced 638 
psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster 639 
randomised trial. BMJ. 2006;332(7544):756-61. 640 
8. Fossey J, Masson S, Stafford J, Lawrence V, Corbett A, Ballard C. The disconnect between 641 
evidence and practice: a systematic review of person-centred interventions and training manuals for 642 
care home staff working with people with dementia. Int J Geriatr Psychiatry. 2014;29(8):797-807. 643 
9. Ballard C, Orrell M, YongZhong S, Moniz-Cook E, Stafford J, Whittaker R, et al. Impact of 644 
Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric 645 
Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-646 
Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) 647 
Program. Am J Psychiatry. 2016;173(3):252-62. 648 
10. Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms 649 
of Alzheimer's disease. Curr Treat Options Neurol. 2012;14(2):113-25. 650 
11. Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, et al. A 1-year follow-651 
up study of behavioral and psychological symptoms in dementia among people in care 652 
environments. The Journal of clinical psychiatry. 2001;62(8):631-6. 653 
12. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nature reviews 654 
Neuroscience. 2006;7(6):492-500. 655 
13. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of 656 
atypical antipsychotic drugs in patients with Alzheimer's disease. The New England journal of 657 
medicine. 2006;355(15):1525-38. 658 
14. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The 659 
dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-660 
controlled trial. The Lancet Neurology. 2009;8(2):151-7. 661 
15. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management 662 
of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245-55. 663 
16. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of 664 
behavioral and psychological symptoms in dementia, with a particular focus on longer term 665 
outcomes and mortality. Expert Opin Drug Saf. 2011;10(1):35-43. 666 
17. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment 667 
for dementia: meta-analysis of randomized placebo-controlled trials. JAMA : the journal of the 668 
American Medical Association. 2005;294(15):1934-43. 669 
18. Alzheimer's Society. Optimising treatment and care for behavioural and psychological 670 
symptoms of dementia: A best practice guide Optimising treatment and care for behavioural and 671 
psychological symptoms of dementia: A best practice guide2012 [ 672 
19. Centre for Medicare and Medicaid Services Office of Clinical Standards and Quality: CMS 673 
2012 Nursing Home Action Plan: Action Plan for Further Improvement of Nursing Home Quality. In: 674 
Services UDoHaH, editor. 2012. 675 
33 
 
20. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of 676 
citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA : the journal 677 
of the American Medical Association. 2014;311(7):682-91. 678 
21. Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect 679 
of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A 680 
Randomized Clinical Trial. JAMA : the journal of the American Medical Association. 681 
2015;314(12):1242-54. 682 
22. Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioral treatment of depression in dementia 683 
patients: a controlled clinical trial. The journals of gerontology Series B, Psychological sciences and 684 
social sciences. 1997;52(4):P159-66. 685 
23. Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a 686 
controlled trial of systematic individualized intervention. The journals of gerontology Series A, 687 
Biological sciences and medical sciences. 2007;62(8):908-16. 688 
24. Moniz Cook ED, Swift K, James I, Malouf R, De Vugt M, Verhey F. Functional analysis-based 689 
interventions for challenging behaviour in dementia. Cochrane Database Syst Rev. 2012;2:CD006929. 690 
25. Whitaker R, Fossey J, Ballard C, Orrell M, Moniz-Cook E, Woods RT, et al. Improving Well-691 
being and Health for People with Dementia (WHELD): study protocol for a randomised controlled 692 
trial. Trials. 2014;15:284. 693 
26. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 694 
1993;43(11):2412-4. 695 
27. Auer S, Reisberg B. The GDS/FAST staging system. Int Psychogeriatr. 1997;9 Suppl 1:167-71. 696 
28. Mulhern B, Rowen D, Brazier J, Smith S, Romeo R, Tait R, et al. Development of DEMQOL-U 697 
and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY 698 
for use in economic evaluation. Health Technol Assess. 2013;17(5):v-xv, 1-140. 699 
29. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. 700 
Journal of gerontology. 1989;44(3):M77-84. 701 
30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The 702 
Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 703 
1994;44(12):2308-14. 704 
31. Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, et al. The use of the 705 
neuropsychiatric inventory in nursing home residents. Characterization and measurement. The 706 
American journal of geriatric psychiatry : official journal of the American Association for Geriatric 707 
Psychiatry. 2000;8(1):75-83. 708 
32. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in 709 
Dementia. Biological psychiatry. 1988;23(3):271-84. 710 
33. Reynolds T, Thornicroft G, Abas M, Woods B, Hoe J, Leese M, et al. Camberwell Assessment 711 
of Need for the Elderly (CANE). Development, validity and reliability. The British journal of psychiatry 712 
: the journal of mental science. 2000;176:444-52. 713 
34. Dean R, Proudfoot, R., Lindesay, J. The quality of interactions schedule (QUIS): Development, 714 
reliability and use in the evaluation of two domus units. Int J Ger Psych. 1993;8(10):819-26. 715 
35. Abbey J, Piller N, De Bellis A, Esterman A, Parker D, Giles L, et al. The Abbey pain scale: a 1-716 
minute numerical indicator for people with end-stage dementia. Int J Palliat Nurs. 2004;10(1):6-13. 717 
36. Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, et al. Cost-effectiveness 718 
analyses for mirtazapine and sertraline in dementia: randomised controlled trial. The British journal 719 
of psychiatry : the journal of mental science. 2013;202:121-8. 720 
37. Knapp M, Iemmi V, Romeo R. Dementia care costs and outcomes: a systematic review. Int J 721 
Geriatr Psychiatry. 2013;28(6):551-61. 722 
38. Russell D, Hoare ZS, Whitaker R, Whitaker CJ, Russell IT. Generalized method for adaptive 723 
randomization in clinical trials. Statistics in medicine. 2011;30(9):922-34. 724 
39. Ballard C, Orrell M, YongZhong S, Moniz-Cook E, Stafford J, Whittaker R, et al. Impact of 725 
Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric 726 
34 
 
Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-727 
Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) 728 
Program. American Journal of Psychiatry. 2016;173(3):252-62. 729 
40. Data from: Impact of person-centered care training and person-centered activities on quality 730 
of life, agitation and antipsychotic use in people with dementia living in nursing homes: A cluster-731 
randomized controlled trial [Internet]. 2014. Available from: 732 
http://dx.doi.org/10.5061/dryad.t903h". 733 
41. Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Determinants of quality of 734 
life in nursing home residents with dementia. Dementia and geriatric cognitive disorders. 735 
2010;29(3):189-97. 736 
42. Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, et al. A randomised, 737 
blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the 738 
DART-AD trial). PLoS medicine. 2008;5(4):e76. 739 
43. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic 740 
treatment in dementia. Journal of the American Geriatrics Society. 1990;38(5):553-63. 741 
 742 
Supporting Information Legends 743 
S1 Text: CONSORT Chart showing flow of participants through the none-month study. 847 744 
participants were randomized, of whom 757 were included in the full imputation analysys 745 
S2 Text: Data analysis protocol for the randomized controlled trial, as developed for this study 746 
and the associated factorial study [25] 747 
S1 Table: Summary and Examples of WHELD Training 748 
Fig 1 Click here to download Figure Fig1.tif 
  
Supporting Information
Click here to access/download
Supporting Information
WHELDData Analysis Section Submitted
Paper.docxCB.docx
  
Supporting Information
Click here to access/download
Supporting Information
Ballard_WHELD_CONSORT checklist.pdf
  
S1 Table
Click here to access/download
Supporting Information
S1_Table.docx
  
CONSORT Checklist
Click here to access/download
Supporting Information
Ballard_CONSORT Checklist.pdf
  
WHELD trial protocol
Click here to access/download
Other
Ballard_WHELD_Trial protocol.pdf
  
CONSORT Diagram
Click here to access/download
Other
Ballard_WHELD_CONSORT.jpg
  
Ethics Approval Letter 1
Click here to access/download
Other
Ballard_WHELD_Ethics Favourable Opinion Letter.pdf
  
Ethics Approval Letter 2 (Final Approval)
Click here to access/download
Other
Ballard_WHELD_Ethics Final Approval Letter.pdf
